The AHEAD-MERIT clinical trial will take place in 15 hospitals in England, targeting patients with aggressive human papillomavirus (HPV)-associated cancers. These cancers have high rates of recurrence and poor survival. The vaccine being developed targets proteins commonly found in HPV-associated head and neck cancer. The health secretary declared the initiative a "huge victory" and NHS England is working with BioNTech to identify eligible patients. This is the third trial under the NHS Cancer Vaccine Launch Pad, which has already supported 550 patients.
Sources
Latest News
14:11
EXCLUSIVE The top themes in domestic politics in trends, in the last week
14:09
Smoke above Timișoara from the vegetation fires in Serbia
14:03
Nicușor Dan condemns, in his first reaction after the destruction of the drone near Neptun Deep, "the intensification of these types of irresponsible incidents by the Russian Federation"
14:01
The Spanish government has announced the establishment of accommodation centers for 1,800 migrants in Ceuta
13:54
Marine drone destroyed near Neptun Deep / MapN clarifications
See more news